Evidence map›Paper›PMID 39640145›Full record

ArticleCureus2024

Coverage of Second Dose of Measles-Containing Vaccine (MCV-2) and Japanese Encephalitis Vaccine (JE-2) and Its Predictors Among Children 2-5 Years Old in the Ormanjhi Block of Ranchi, Jharkhand, India: A Mixed Method Study.

Ankita Mukul, Shashi B Singh, Vidya Sagar, Dilip K Paswan, Smiti Narain, Dewesh Kumar

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ankita MukulDepartment of Community Medicine, Rajendra Institute of Medical Sciences, Ranchi, IND.
Shashi B SinghDepartment of Community Medicine, Rajendra Institute of Medical Sciences, Ranchi, IND.
Vidya SagarDepartment of Community Medicine, Rajendra Institute of Medical Sciences, Ranchi, IND.
Dilip K PaswanDepartment of Community Medicine, Rajendra Institute of Medical Sciences, Ranchi, IND.
Smiti NarainDepartment of Community Medicine, Rajendra Institute of Medical Sciences, Ranchi, IND.
Dewesh KumarDepartment of Community Medicine/Preventive and Social Medicine, Rajendra Institute of Medical Sciences, Ranchi, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Administering the measles vaccine at an appropriate age and dosage in children is important for India to eliminate measles, a potentially deadly vaccine-preventable disease. Similarly, the Japanese encephalitis (JE) vaccine, particularly in endemic regions is important to prevent morbidity and high-case fatality from the disease. The study attempts to evaluate the coverage of measles and JE vaccines and their predictors. Materials and methods A mixed method study design, incorporating a three-stage cluster random sampling process was used in the cross-sectional survey conducted among 604 children aged 2-5 years in the Ormanjhi block of Ranchi, Jharkhand, from April 2023 to June 2024. The parents/caregivers of the eligible children were interviewed using a predesigned, pretested semi-structured questionnaire, and the immunization status of children was taken from vaccination cards. A focused group discussion (FGD) and an in-depth interview (IDI) with healthcare providers formed the qualitative component. We conducted descriptive, and logistic regression analysis using the IBM SPSS Statistics for Windows, Version 26 (Released 2019; IBM Corp., Armonk, New York, United States). The association between the coverage of the vaccine and sociodemographic variables was done using the Chi-square test. Logistic regression was used to study the predictors, and a p-value of <0.05 was considered statistically significant. Results In the household survey, the coverage of the measles-containing vaccine first dose (MCV-1) was 594 (98.3%), while the second dose (MCV-2) was 536 (88.7%) out of 604 participants. For the JE vaccine, the coverage of the first dose (JE-1) was 588 (97.4%), while the second dose (JE-2) coverage was 492 (81.5%). In the multivariate logistic regression, religion and the lack of parental knowledge about measles were significant predictors for lower MCV-2 uptake, while the for JE vaccine, religion, father's education, and household head's occupation remained statistically significant factors (p ≤ 0.05). Vaccine hesitancy had mixed perceptions with the child's unavailability being the most significant reason for hesitancy in both MCV and JE vaccinations. In the FGD, child's unavailability at times of vaccination and parent's fear of side effects post vaccination were major factors for missing doses of the vaccine. Conclusion While the initial coverage of MCV and JE vaccines is commendable, the substantial drop in the second dose coverage and the delays in administration present significant challenges.

Indexed as

japanese encephalitisje vaccinemcvmeaslespredictorsvaccination coverage

Identifiers

PMID39640145
PMCPMC11617491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.